Research programme: cancer therapeutics - Tiziana Life SciencesAlternative Names: Anti-cancer stem cell agent - Tiziana; Bcl3i molocules - Cardiff University/ Tiziania Life Sciences; CB1; cFLIP inhibitors; JS6; OH 14; TZLS 214; TZLS101
Latest Information Update: 06 Jun 2016
At a glance
- Originator Cardiff University
- Developer Cardiff University; Tiziana Life Sciences
- Class Small molecules
- Mechanism of Action Apoprotein stimulants; Bcl-X protein inhibitors; Molecular motor protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer; Colorectal cancer